Eli Lilly Net Income 2010-2022 | LLY

Eli Lilly annual/quarterly net income history and growth rate from 2010 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Eli Lilly net income for the quarter ending March 31, 2022 was $1.903B, a 40.4% increase year-over-year.
  • Eli Lilly net income for the twelve months ending March 31, 2022 was $6.129B, a 0.6% increase year-over-year.
  • Eli Lilly annual net income for 2021 was $5.582B, a 9.88% decline from 2020.
  • Eli Lilly annual net income for 2020 was $6.194B, a 25.54% decline from 2019.
  • Eli Lilly annual net income for 2019 was $8.318B, a 157.38% increase from 2018.
Eli Lilly Annual Net Income
(Millions of US $)
2021 $5,582
2020 $6,194
2019 $8,318
2018 $3,232
2017 $-204
2016 $2,738
2015 $2,408
2014 $2,391
2013 $4,685
2012 $4,089
2011 $4,348
2010 $5,070
2009 $4,329
Eli Lilly Quarterly Net Income
(Millions of US $)
2022-03-31 $1,903
2021-12-31 $1,726
2021-09-30 $1,110
2021-06-30 $1,390
2021-03-31 $1,355
2020-12-31 $2,117
2020-09-30 $1,208
2020-06-30 $1,412
2020-03-31 $1,457
2019-12-31 $1,496
2019-09-30 $1,254
2019-06-30 $1,327
2019-03-31 $4,242
2018-12-31 $1,125
2018-09-30 $1,150
2018-06-30 $-260
2018-03-31 $1,217
2017-12-31 $-1,657
2017-09-30 $556
2017-06-30 $1,008
2017-03-31 $-111
2016-12-31 $772
2016-09-30 $778
2016-06-30 $748
2016-03-31 $440
2015-12-31 $478
2015-09-30 $800
2015-06-30 $601
2015-03-31 $530
2014-12-31 $429
2014-09-30 $501
2014-06-30 $734
2014-03-31 $728
2013-12-31 $728
2013-09-30 $1,203
2013-06-30 $1,206
2013-03-31 $1,548
2012-12-31 $827
2012-09-30 $1,327
2012-06-30 $924
2012-03-31 $1,011
2011-12-31 $858
2011-09-30 $1,236
2011-06-30 $1,197
2011-03-31 $1,056
2010-12-31 $1,170
2010-09-30 $1,303
2010-06-30 $1,349
2010-03-31 $1,248
2009-12-31 $915
2009-09-30 $942
2009-06-30 $1,159
2009-03-31 $1,313
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $283.955B $28.318B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $465.705B 17.91
Pfizer (PFE) United States $294.404B 10.27
AbbVie (ABBV) United States $266.851B 11.70
Merck (MRK) United States $236.570B 13.36
Novartis AG (NVS) Switzerland $200.009B 14.40
GlaxoSmithKline (GSK) United Kingdom $113.161B 13.21
Novo Nordisk (NVO) Denmark $0.000B 32.07